Streamline for QRxPharma
Tuesday, 05 August, 2008
The US Food and Drug Administration has granted approval to QRxPharma's [ASX: QRX] streamlined Phase III development plan for lead candidate Q8003IR.
This approval means that QRxPharma will be required to conduct only two Phase III trials for New Drug Agreement [NDA] filing. No additional pharmacology, toxicology or long term clinical safety studies will be required.
Q8003IR is an immediate release dual-opioid containing both morphine and oxycodone, and is intended to be used in the management of moderate to severe pain.
The FDA did make some changes to QRxPharma's proposal, but according to company representatives these changes were minimal.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
